ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer.
作者信息
Della Corte Carminia Maria, Gay Carl Michael, Byers Lauren Averett, Morgillo Floriana
机构信息
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
出版信息
EBioMedicine. 2019 Jan;39:5-6. doi: 10.1016/j.ebiom.2018.12.008. Epub 2018 Dec 13.
Abstract
摘要
相似文献
1
ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer.整合素连接激酶（ILK）和含Src同源2结构域蛋白酪氨酸磷酸酶2（SHP2）的表达确定了表皮生长因子受体（EGFR）突变型肺癌的一个预后不良队列。
EBioMedicine. 2019 Jan;39:5-6. doi: 10.1016/j.ebiom.2018.12.008. Epub 2018 Dec 13.
2
Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.在肺腺癌转基因小鼠模型中，抑制Shp2可抑制突变型EGFR诱导的肺肿瘤。
Oncotarget. 2015 Mar 20;6(8):6191-202. doi: 10.18632/oncotarget.3356.
3
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients.MUC1（上皮唾液酸蛋白）在非小细胞肺癌中的表达独立于表皮生长因子受体（EGFR）和c-erbB-2的表达，且与淋巴结阳性患者的不良生存相关。
J Clin Pathol. 1998 Sep;51(9):667-71. doi: 10.1136/jcp.51.9.667.
4
Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.中性粒细胞与淋巴细胞比值作为接受酪氨酸激酶抑制剂治疗的欧洲表皮生长因子受体突变型非小细胞肺癌患者的预后因素。
Oncol Res Treat. 2018;41(12):755-761. doi: 10.1159/000492344. Epub 2018 Nov 13.
5
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.HER-2、表皮生长因子受体（EGFR）、环氧化酶-2（COX-2）的表达状态与接受手术切除的非小细胞肺癌中的微血管密度及生存率相关。
Acta Oncol. 2004;43(1):80-6. doi: 10.1080/02841860310017441.
6
Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis.无脑转移的表皮生长因子受体突变型非小细胞肺癌患者胸腔积液的预后影响。
Thorac Cancer. 2019 Mar;10(3):557-563. doi: 10.1111/1759-7714.12979. Epub 2019 Jan 23.
7
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.表皮生长因子受体和HER2-neu蛋白的同步过表达是I期非小细胞肺癌患者预后不良的一个预测指标。
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43. doi: 10.1158/1078-0432.ccr-0373-3.
8
Over-expression of EGFR is closely correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma.在突尼斯非小细胞肺腺癌患者中，表皮生长因子受体（EGFR）的过表达与不良预后密切相关。
J Immunoassay Immunochem. 2014;35(3):256-68. doi: 10.1080/15321819.2013.848813.
9
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.基于 cBioPortal 数据库的分析：晚期非小细胞肺癌中 TP53 的预后价值及其与 EGFR 突变的相关性。
Lung Cancer. 2018 Sep;123:70-75. doi: 10.1016/j.lungcan.2018.07.003. Epub 2018 Jul 4.
10
Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.晚期非小细胞肺癌经第一代 EGFR TKI 治疗有效后发生脑膜转移。
Lung Cancer. 2019 Jan;127:1-5. doi: 10.1016/j.lungcan.2018.11.022. Epub 2018 Nov 20.
引用本文的文献
1
A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).特定的氨基酸序列在 EGFR 和 HER2 的磷酸化位点，使其能够选择性地与Src 同源磷酸酶 2（SHP2）的活性位点结合。
J Biol Chem. 2020 Mar 13;295(11):3563-3575. doi: 10.1074/jbc.RA119.011422. Epub 2020 Feb 4.
本文引用的文献
1
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).整合素连接激酶（ILK）和 src 同源 2 结构域磷酸酶 2（SHP2）：表皮生长因子受体突变阳性非小细胞肺癌（NSCLC）的新靶点。
EBioMedicine. 2019 Jan;39:207-214. doi: 10.1016/j.ebiom.2018.11.036. Epub 2018 Nov 22.
2
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.联合抑制 MEK 和 PI3K 通路可克服非小细胞肺癌对 EGFR-TKIs 的获得性耐药。
Cancer Sci. 2018 Oct;109(10):3183-3196. doi: 10.1111/cas.13763. Epub 2018 Sep 14.
3
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.NCCN 指南解读：非小细胞肺癌，第 5 版，2018 年。
J Natl Compr Canc Netw. 2018 Jul;16(7):807-821. doi: 10.6004/jnccn.2018.0062.
4
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.奥希替尼联合 Selumetinib 或 Cetuximab 双重阻断 EGFR 信号对激活 EGFR 的人非小细胞肺癌肿瘤模型的抗肿瘤疗效。
J Thorac Oncol. 2018 Jun;13(6):810-820. doi: 10.1016/j.jtho.2018.02.025. Epub 2018 Mar 8.
5
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.表皮生长因子受体突变阳性非小细胞肺癌中 AXL 和 CDCP1 的共同激活与不良预后相关。
EBioMedicine. 2018 Mar;29:112-127. doi: 10.1016/j.ebiom.2018.02.001. Epub 2018 Feb 5.
6
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.SFK/FAK信号通路减弱了奥希替尼在EGFR突变型肺癌的药物敏感和耐药模型中的疗效。
Cancer Res. 2017 Jun 1;77(11):2990-3000. doi: 10.1158/0008-5472.CAN-16-2300. Epub 2017 Apr 17.
7
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.表皮生长因子受体（EGFR）突变的非小细胞肺癌中信号转导及转录激活因子3（STAT3）与Yes相关蛋白1（YAP1）通路的共激活
J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx014.
8
Mechanisms of resistance to EGFR-targeted drugs: lung cancer.表皮生长因子受体（EGFR）靶向药物的耐药机制：肺癌
ESMO Open. 2016 May 11;1(3):e000060. doi: 10.1136/esmoopen-2016-000060. eCollection 2016.
9
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.SMO 基因扩增和 Hedgehog 通路的激活是人类肺癌对表皮生长因子受体药物产生耐药性的新机制。
Clin Cancer Res. 2015 Oct 15;21(20):4686-97. doi: 10.1158/1078-0432.CCR-14-3319. Epub 2015 Jun 29.
10
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.上皮-间充质转化基因特征可预测对 EGFR 和 PI3K 抑制剂的耐药性，并确定 Axl 作为克服 EGFR 抑制剂耐药性的治疗靶点。
Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.
Zotero 插件